|
1
|
Dangas G and Kuepper F: Cardiology patient
page. Restenosis: repeat narrowing of a coronary artery: prevention
and treatment. Circulation. 105:2586–2587. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Boger RH: Asymmetric dimethylarginine
(ADMA) and cardiovascular disease: insights from prospective
clinical trials. Vasc Med. 10:S19–S25. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lau HK, Segev A, Hegele RA, Sparkes JD,
Teitel JM, et al: Thrombin-activatable fibrinolysis inhibitor
(TAFI): a novel predictor of angiographic coronary restenosis.
Thromb Haemost. 90:1187–1191. 2003.PubMed/NCBI
|
|
4
|
Gad MZ, Hassanein SI, Abdel-Maksoud SM,
Shaban GM, Abou-Aisha K, et al: Assessment of serum levels of
asymmetric dimethylarginine (ADMA), symmetric dimethylarginine
(SDMA) and L-arginine in coronary artery disease. Biomarkers.
15:746–752. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Loscalzo J and Welch G: Nitric oxide and
its role in the cardiovascular system. Prog Cardiovasc Dis.
38:87–104. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hogg N, Kalyanaraman B, Joseph J, Struck A
and Parthasarathy S: Inhibition of low-density lipoprotein
oxidation by nitric oxide. Potential role in atherogenesis. FEBS
Lett. 334:170–174. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Marks DS, Vita JA, Folts JD, Keaney JF Jr,
Welch GN, et al: Inhibition of neointimal proliferation in rabbits
after vascular injury by a single treatment with a protein adduct
of nitric oxide. J Clin Invest. 96:2630–2638. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Garg UC and Hassid A: Nitric
oxide-generating vasodilators and 8-bromo-cyclic guanosine
monophosphate inhibit mitogenesis and proliferation of cultured rat
vascular smooth muscle cells. J Clin Invest. 83:1774–1777. 1989.
View Article : Google Scholar
|
|
9
|
Valkonen VP, Paiva H, Salonen JT, Lakka
TA, Lehtimaki T, et al: Risk of acute coronary events and serum
concentration of asymmetrical dimethylarginine. Lancet.
358:2127–2128. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zoccali C, Bode-Boger S, Mallamaci F,
Benedetto F, Tripepi G, et al: Plasma concentration of asymmetrical
dimethylarginine and mortality in patients with end-stage renal
disease: a prospective study. Lancet. 358:2113–2117. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Janero DR and Ewing JF: Nitric oxide and
postangioplasty restenosis: pathological correlates and therapeutic
potential. Free Radic Biol Med. 29:1199–1221. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lu TM, Ding YA, Charng MJ and Lin SJ:
Asymmetrical dimethylarginine: a novel risk factor for coronary
artery disease. Clin Cardiol. 26:458–464. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wykretowicz A, Metzler L, Milewska A,
Balinski M, Rutkowska A, et al: Noninvasively assessed pulsatility
of ascending aortic pressure waveform is associated with the
presence of coronary artery narrowing. Heart Vessels. 23:16–19.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schulze F, Lenzen H, Hanefeld C, Bartling
A, Osterziel KJ, et al: Asymmetric dimethylarginine is an
independent risk factor for coronary heart disease: results from
the multicenter Coronary Artery Risk Determination investigating
the Influence of ADMA Concentration (CARDIAC) study. Am Heart J.
152:493 e1–8. 2006.
|
|
15
|
Boger RH: Asymmetric dimethylarginine, an
endogenous inhibitor of nitric oxide synthase, explains the
‘L-arginine paradox’ and acts as a novel cardiovascular risk
factor. J Nutr. 134:2842S–2847S. 2004.
|
|
16
|
Sahinarslan A, Cengel A, Biberoglu G,
Hasanoglu A, Turkoglu S, et al: Plasma asymmetric dimethylarginine
level and extent of lesion at coronary angiography. Coron Artery
Dis. 17:605–609. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cziraki A, Ajtay Z, Nemeth A, Lenkey Z,
Sulyok E, et al: Effects of coronary revascularization with or
without cardiopulmonary bypass on plasma levels of asymmetric
dimethylarginine. Coron Artery Dis. 22:245–252. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ajtay Z, Scalera F, Cziraki A, Horvath I,
Papp L, et al: Stent placement in patients with coronary heart
disease decreases plasma levels of the endogenous nitric oxide
synthase inhibitor ADMA. Int J Mol Med. 23:651–657. 2009.PubMed/NCBI
|
|
19
|
Krempl TK, Maas R, Sydow K, Meinertz T,
Boger RH, et al: Elevation of asymmetric dimethylarginine in
patients with unstable angina and recurrent cardiovascular events.
Eur Heart J. 26:1846–1851. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu CC, Wen SC, Yang CW, Pu SY, Tsai KC, et
al: Plasma ADMA predicts restenosis of arteriovenous fistula. J Am
Soc Nephrol. 20:213–222. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Paola Cellai A, Antonucci E, Alessandrello
Liotta A, Fedi S, Marcucci R, et al: TAFI activity and antigen
plasma levels are not increased in acute coronary artery disease
patients admitted to a coronary care unit. Thromb Res. 118:495–500.
2006.PubMed/NCBI
|
|
22
|
Jang Y, Guzman LA, Lincoff AM,
Gottsauner-Wolf M, Forudi F, et al: Influence of blockade at
specific levels of the coagulation cascade on restenosis in a
rabbit atherosclerotic femoral artery injury model. Circulation.
92:3041–3050. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
van Tilburg NH, Rosendaal FR and Bertina
RM: Thrombin activatable fibrinolysis inhibitor and the risk for
deep vein thrombosis. Blood. 95:2855–2859. 2000.PubMed/NCBI
|
|
24
|
Silveira A, Schatteman K, Goossens F, Moor
E, Scharpe S, et al: Plasma procarboxypeptidase U in men with
symptomatic coronary artery disease. Thromb Headmost. 84:364–368.
2000.PubMed/NCBI
|
|
25
|
Morange PE, Juhan-Vague I, Scarabin PY,
Alessi MC, Luc G, et al: Association between TAFI antigen and
Ala147Thr polymorphism of the TAFI gene and the angina pectoris
incidence. The PRIME Study (Prospective Epidemiological Study of
MI). Thromb Haemost. 89:554–560. 2003.PubMed/NCBI
|
|
26
|
Eichinger S, Schonauer V, Weltermann A,
Minar E, Bialonczyk C, et al: Thrombin-activatable fibrinolysis
inhibitor and the risk for recurrent venous thromboembolism. Blood.
103:3773–3776. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Juhan-Vague I, Morange PE, Aubert H, Henry
M, Aillaud MF, et al: Plasma thrombin-activatable fibrinolysis
inhibitor antigen concentration and genotype in relation to
myocardial infarction in the north and south of Europe.
Arterioscler Thromb Vasc Biol. 22:867–873. 2002. View Article : Google Scholar
|
|
28
|
Juhan-Vague I and Morange PE: Very high
TAFI antigen levels are associated with a lower risk of hard
coronary events: the PRIME Study. J Thromb Haemost. 1:2243–2244.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bouma BN and Mosnier LO: Thrombin
activatable fibrinolysis inhibitor (TAFI) at the interface between
coagulation and fibrinolysis. Pathophysiol Haemost Thromb.
33:375–381. 2003. View Article : Google Scholar : PubMed/NCBI
|
